Literature DB >> 11669163

Clinical and laboratory features of anticentromere antibody positive primary Sjögren's syndrome.

K Katano1, M Kawano, I Koni, S Sugai, Y Muro.   

Abstract

OBJECTIVE: To determine whether the clinical and laboratory characteristics of anticentromere antibody (ACA) positive, anti-SSA/Ro antibody (SSA) negative primary Sjogren's syndrome (SS) differ from SSA positive, ACA negative primary SS.
METHODS: Twelve patients with ACA positive primary SS (ACA SS) and 19 patients with SSA positive primary SS (SSA SS) were examined. We compared the age, laboratory data, proportion with Raynaud's phenomenon (RP), activity of natural killer cells (NK), titer of antibodies against Epstein-Barr virus, and histological findings of minor labial salivary glands. The presence of anti-chromo antibodies (AChA) was evaluated by immunoblotting of patients' sera.
RESULTS: The mean age of the ACA SS group was higher than that of the SSA SS group (p < 0.05). Serum IgG level was lower in ACA SS than in SSA SS (p < 0.0001). Serum IgG level of the ACA SS group with one exception was close to the normal range. Leukocytopenia was less frequently observed in ACA SS than in SSA SS (p < 0.05). RP was seen more frequently in the ACA SS group than the SSA SS group (p < 0.05). NK activity of the ACA SS group was higher than that of the SSA SS group (p < 0.05). Most of the ACA SS patients' NK activity was normal, in contrast to the tendency for NK activity in SS to be low. Virus capsid antigen IgA titer of the ACA SS group was lower than that of the SSA SS group (p < 0.05). Histological findings of minor labial salivary glands of both groups showed a similar severity of lymphocytic infiltrates, destruction of normal structures, and pattern of infiltrating lymphocyte subsets. AChA was positive in 11 of the 12 sera of ACA SS patients.
CONCLUSION: The results confirm that ACA positive primary SS differs from SSA positive classic SS in several significant respects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11669163

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  20 in total

Review 1.  Autoantibodies in Sjögren's Syndrome.

Authors:  Anum Fayyaz; Biji T Kurien; R Hal Scofield
Journal:  Rheum Dis Clin North Am       Date:  2016-06-21       Impact factor: 2.670

2.  The value of pattern capillary changes and antibodies to predict the development of systemic sclerosis in patients with primary Raynaud's phenomenon.

Authors:  Slavica R Pavlov-Dolijanovic; Nemanja S Damjanov; Nada Z Vujasinovic Stupar; Snezana Baltic; Dragan D Babic
Journal:  Rheumatol Int       Date:  2013-08-11       Impact factor: 2.631

3.  Distinct recognition of antibodies to centromere proteins in primary Sjogren's syndrome compared with limited scleroderma.

Authors:  A C Gelber; S R Pillemer; B J Baum; F M Wigley; L K Hummers; S Morris; A Rosen; L Casciola-Rosen
Journal:  Ann Rheum Dis       Date:  2006-01-13       Impact factor: 19.103

4.  Primary Sjogren's syndrome with anticentromere antibodies--a clinically distinct subset.

Authors:  Dhiraj Gulati; Irving Kushner; Elizabeth File; Marina Magrey
Journal:  Clin Rheumatol       Date:  2010-01-19       Impact factor: 2.980

5.  Clinical significance and diagnostic usefulness of anti-centromere antibody in Sjögren's syndrome.

Authors:  Tetsutaro Kitagawa; Koichi Shibasaki; Shuji Toya
Journal:  Clin Rheumatol       Date:  2011-06-14       Impact factor: 2.980

6.  Anti-centromere antibody is an independent risk factor for chronic kidney disease in patients with primary biliary cirrhosis.

Authors:  Shintaro Mandai; Eiichiro Kanda; Yohei Arai; Suguru Hirasawa; Toshiyuki Hirai; Shota Aki; Naoto Inaba; Makoto Aoyagi; Hiroyuki Tanaka; Takaaki Ikeda; Teiichi Tamura; Sei Sasaki
Journal:  Clin Exp Nephrol       Date:  2012-12-26       Impact factor: 2.801

7.  The value of antinuclear antibodies in primary biliary cirrhosis.

Authors:  Lixia Gao; Xinping Tian; Bin Liu; Fengchun Zhang
Journal:  Clin Exp Med       Date:  2008-04-03       Impact factor: 3.984

8.  Prognostic value of Sjögren's syndrome autoantibodies.

Authors:  R Hal Scofield; Anum Fayyaz; Biji T Kurien; Kristi A Koelsch
Journal:  J Lab Precis Med       Date:  2018-10-30

9.  Anticentromere antibody positive Sjögren's Syndrome: a retrospective descriptive analysis.

Authors:  Vasiliki-Kalliopi K Bournia; Konstantina D Diamanti; Panayiotis G Vlachoyiannopoulos; Haralampos M Moutsopoulos
Journal:  Arthritis Res Ther       Date:  2010-03-13       Impact factor: 5.156

10.  Anti-centromere antibody-seropositive Sjögren's syndrome differs from conventional subgroup in clinical and pathological study.

Authors:  Hideki Nakamura; Atsushi Kawakami; Tomayoshi Hayashi; Naoki Iwamoto; Akitomo Okada; Mami Tamai; Satoshi Yamasaki; Hiroaki Ida; Katsumi Eguchi
Journal:  BMC Musculoskelet Disord       Date:  2010-07-01       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.